Shahid Nimjee Email
Founder, Chief Medical Officer . Basking Biosciences
How to contact Shahid Nimjee
Join and see Shahid's contact info for free!Current Roles
Employees:
12Revenue:
$1.9MAbout
Basking Biosciences is developing a novel first-line therapy (BB-031) targeting von Willebrand Factor (vWF), along with a direct acting reversal agent (BB-025) to immediately neutralize the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. BB-031 is being evaluated in patients with acute ischemic stroke (AIS) in the RAISE trial, a two-part Phase 2 study assessing the safety and preliminary efficacy of the investigational drug candidate. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.\n \n\n \n \n Show more\n \n\n \n\n\n \n \n Show lessBasking Biosciences Address
Columbus, OH
United States